Single-target approaches have failed in PSP because the disease requires simultaneous addressing of protein pathology AND circuit dysfunction. This combination therapy coordinates 4R-tau reduction (via ASO or small molecule), neuroinflammation modulation (via NLRP3 inhibition or microglial reprogramming), and brainstem circuit support (via GABAergic modulation or neurotrophic factors).[@golbe2014][@lees2017]
Single-target approaches have failed in PSP because the disease requires simultaneous addressing of protein pathology AND circuit dysfunction. This combination therapy coordinates 4R-tau reduction (via ASO or small molecule), neuroinflammation modulation (via NLRP3 inhibition or microglial reprogramming), and brainstem circuit support (via GABAergic modulation or neurotrophic factors).[@golbe2014][@lees2017]
Target Type: Combination of ASO + small molecule + small molecule
Expression: Target expressed in neurons (tau), microglia (NLRP3), and brainstem neurons (GABA receptors)
Localization: CNS-wide; brainstem-focused for circuit component
Mechanistic Rationale
PSP pathology involves three interconnected mechanisms that must be addressed simultaneously:[@golbe2014]
4R-tau accumulation: MAPT exon 10 +2 splice site mutations cause exclusive 4R-tau production. 4R-tau aggregates in subcortical neurons, leading to neurofibrillary tangles in basal ganglia, subthalamic nucleus, and brainstem. Single ASO targeting exon 10 has shown preclinical promise.
Neuroinflammation: PSP brains show marked glial activation in affected regions. NLRP3 inflammasome activation in microglia drives IL-1β and IL-18 release, promoting tau phosphorylation and propagation. Anti-inflammatory approaches have shown benefit in PSP models.
Brainstem circuit dysfunction: Tau pathology in brainstem nuclei (PPN, superior colliculus, red nucleus) causes the characteristic vertical gaze palsy, postural instability, and dysphagia. GABAergic signaling deficits in these circuits contribute to circuit hypofunction.
Mermaid diagram (expand to render)
Rubric Score
| Dimension | Score | Rationale | |-----------|-------|-----------| | Novelty | 9/10 | First combination approach specifically for PSP; addresses tri-part pathology | | Mechanistic Rationale | 8/10 | Each component has independent rationale; combination addresses multiple pathways | | Addresses Root Cause | 8/10 | Targets tau directly + downstream consequences + circuit dysfunction | | Delivery Feasibility | 7/10 | ASO delivery via intrathecal; small molecules oral; brainstem targeting achievable | | Safety Plausibility | 7/10 | Each component has safety data; combination requires careful titration | | Combinability | 9/10 | Engineered as combination; components selected for synergy | | Biomarker Available | 7/10 | p-tau181, NFL, and CSF inflammatory markers available | | De-risking Path | 8/10 | Each component independently de-risked; combination adds complexity | | Multi-disease Potential | 6/10 | Primarily PSP; may apply to CBD and other 4R-tauopathies | | Patient Impact | 8/10 | Addresses core symptoms: gaze palsy, gait instability, dysphagia | | Total | 77/100 | |
De-risking Path
Phase 1 — Component validation: Test each component individually in PSP iPSC models and mouse models
Phase 2 — Combination optimization: Test component combinations in vitro; identify synergistic vs. additive effects
Phase 3 — Model efficacy: Test lead combination in P501L or other PSP mouse model; measure tau, inflammation, and circuits
| Disease | Relevance | Rationale | |---------|-----------|-----------| | Progressive Supranuclear Palsy | High | Primary indication; addresses all three pathological features | | Corticobasal Degeneration | Medium | Similar 4R-tauopathy; may benefit from tau reduction | | Aging | Medium | Age is primary risk factor; neuroinflammation increases with age |
Combination Therapy Components
Component 1: 4R-Tau Targeting
Mechanism: ASO targeting MAPT exon 10 +2 splice site to shift 4R/3R ratio
Lead: ASO-004 (hMAPT exon 10 targeting)
Dose: 120mg intrathecal monthly
Status: Preclinical validation complete
Component 2: Neuroinflammation Modulation
Mechanism: NLRP3 inflammasome inhibitor to reduce microglial activation
[Nichols E, Szoeke C, Steiner ML, et al, The global, regional, and national burden of Alzheimer's disease and vascular dementia, 1990–2016 (2020)](https://pubmed.ncbi.nlm.nih.gov/31623041/)
[Hood L, Chen S, Joyce B, et al, Targeting neuroinflammation in progressive supranuclear palsy (2023)](https://pubmed.ncbi.nlm.nih.gov/37615678/)
[Golbe LI, Progressive supranuclear palsy: a review of the disease and its treatment (2014)](https://pubmed.ncbi.nlm.nih.gov/25464523/)
[Lees AJ, Boxer AL, Galna B, et al, Developing tau-targeting therapies for Progressive Supranuclear Palsy (2017)](https://pubmed.ncbi.nlm.nih.gov/28283582/)
[Stamelou M, dehos L, Dubois B, et al, Developing first disease-modifying treatments for Progressive Supranuclear Palsy (2010)](https://pubmed.ncbi.nlm.nih.gov/20506199/)
[Litvan I, Agid Y, Calne D, et al, Clinical research into neuroprotective therapies for PSP (2011)](https://pubmed.ncbi.nlm.nih.gov/21931279/)
[Apicco DJ, Feinstein DL, Simon JA, Neuroinflammation and astroglial responses in progressive supranuclear palsy (2018)](https://pubmed.ncbi.nlm.nih.gov/29349782/)
[Koga S, Zhou CH, Kartefi L, et al, CSF biomarkers for progressive supranuclear palsy (2021)](https://pubmed.ncbi.nlm.nih.gov/34301461/)